Literature DB >> 19459590

Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.

Qian Sun1, T Chris Gamblin.   

Abstract

The microtubule-associated protein tau, in a hyperphosphorylated form, aggregates into insoluble paired-helical filaments (PHFs) in Alzheimer's disease (AD) and other tauopathies. In AD, there is approximately 8 mol of phosphate per mole of tau distributed among approximately 30 PHF phosphorylation sites as compared to 2-3 mol of phosphate per mole in normal brain. In AD, kinases such as glycogen synthase kinase-3beta (GSK-3beta) are believed to be involved in the generation of hyperphosphorylated tau. However, the functional consequences of hyperphosphorylation on the microtubule binding and polymerization of tau are not well understood. To address this question, we have generated pseudohyperphosphorylation mutants consisting of six and seven sites in the proline-rich region and carboxy terminus of tau by amino acid substitution. In addition, several single, double, and triple pseudophosphorylation mutants were also generated. Pseudophosphorylation of tau decreases its affinity for microtubules, and pseudohyperphosphorylated forms of tau do not have significantly decreased levels of microtubule binding as compared to single and double sites. Three pseudohyperphosphorylated forms of tau with altered sodium dodecyl sulfate-polyacrylamide gel electrophoresis migration have a greater effect on its inducer-mediated polymerization, slowing the rate of nucleation and elongation. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19459590      PMCID: PMC2739831          DOI: 10.1021/bi900602h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  60 in total

1.  A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease.

Authors:  G A Jicha; E Lane; I Vincent; L Otvos; R Hoffmann; P Davies
Journal:  J Neurochem       Date:  1997-11       Impact factor: 5.372

Review 2.  Tau protein as a differential biomarker of tauopathies.

Authors:  Nicolas Sergeant; André Delacourte; Luc Buée
Journal:  Biochim Biophys Acta       Date:  2005-01-03

3.  Pre-assembled tau filaments phosphorylated by GSK-3b form large tangle-like structures.

Authors:  Carolyn A Rankin; Qian Sun; T Chris Gamblin
Journal:  Neurobiol Dis       Date:  2008-07-16       Impact factor: 5.996

4.  Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.

Authors:  Thomas Fath; Jochen Eidenmüller; Roland Brandt
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

5.  Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation.

Authors:  Carolyn A Rankin; Qian Sun; T Chris Gamblin
Journal:  Brain Res Mol Brain Res       Date:  2005-07-29

6.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

Review 7.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

8.  Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.

Authors:  E M Mandelkow; G Drewes; J Biernat; N Gustke; J Van Lint; J R Vandenheede; E Mandelkow
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

9.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

10.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

View more
  19 in total

1.  Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.

Authors:  Benjamin Combs; Kellen Voss; T Chris Gamblin
Journal:  Biochemistry       Date:  2011-10-17       Impact factor: 3.162

2.  The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.

Authors:  Silvia Lisa; Massimiliano Meli; Gema Cabello; Ruth Gabizon; Giorgio Colombo; María Gasset
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

Review 3.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

4.  Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

Review 5.  Structural evaluations of tau protein conformation: methodologies and approaches.

Authors:  Nicole L Zabik; Matthew M Imhof; Sanela Martic-Milne
Journal:  Biochem Cell Biol       Date:  2017-03-09       Impact factor: 3.626

6.  Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation.

Authors:  Christopher L Moore; Michael H Huang; Shauna A Robbennolt; Kellen R Voss; Benjamin Combs; T Chris Gamblin; Warren J Goux
Journal:  Biochemistry       Date:  2011-11-29       Impact factor: 3.162

7.  Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.

Authors:  Nicholas M Kanaan; Gerardo Morfini; Gustavo Pigino; Nichole E LaPointe; Athena Andreadis; Yuyu Song; Ellen Leitman; Lester I Binder; Scott T Brady
Journal:  Neurobiol Aging       Date:  2011-07-27       Impact factor: 4.673

8.  Tau Kinetics in Neurons and the Human Central Nervous System.

Authors:  Chihiro Sato; Nicolas R Barthélemy; Kwasi G Mawuenyega; Bruce W Patterson; Brian A Gordon; Jennifer Jockel-Balsarotti; Melissa Sullivan; Matthew J Crisp; Tom Kasten; Kristopher M Kirmess; Nicholas M Kanaan; Kevin E Yarasheski; Alaina Baker-Nigh; Tammie L S Benzinger; Timothy M Miller; Celeste M Karch; Randall J Bateman
Journal:  Neuron       Date:  2018-03-21       Impact factor: 17.173

9.  Hsp70 alters tau function and aggregation in an isoform specific manner.

Authors:  Kellen Voss; Benjamin Combs; Kristina R Patterson; Lester I Binder; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-01-23       Impact factor: 3.162

10.  FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions.

Authors:  Benjamin Combs; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-10-18       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.